-

05:48:28 AM

KOD Stock News

KOD - Kodiak Sciences Inc

08/09/22 4:33 PM

Nasdaq : KOD

earnings

Kodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results

RHEA-AI

positive

08/08/22 6:30 AM

Nasdaq : KOD

clinical trial

Kodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein Occlusion

Tarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every month First anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the treatment interval in patients with RVO Tarcocimab

RHEA-AI

positive

08/05/22 4:30 PM

Nasdaq : KOD

clinical trial

Kodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its

RHEA-AI

neutral

05/27/22 8:00 AM

Nasdaq : KOD

conferences

Kodiak Sciences to Present at the Jefferies Global Healthcare Conference

PALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies Global

RHEA-AI

neutral

05/19/22 8:00 AM

Nasdaq : KOD

Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal Diseases

Purpose-built bioconjugation facility in Lonza's Ibex ® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion of

RHEA-AI

positive

05/10/22 4:10 PM

Nasdaq : KOD

earnings

Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results

RHEA-AI

positive

04/29/22 5:30 AM

Nasdaq : KOD

clinical trial

Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations of clinical study

RHEA-AI

neutral

03/01/22 4:10 PM

Nasdaq : KOD

earnings

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial results

RHEA-AI

neutral

02/23/22 6:00 AM

Nasdaq : KOD

clinical trial

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Kodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b /3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer

RHEA-AI

neutral

02/03/22 5:30 AM

Nasdaq : KOD

clinical trial

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its

RHEA-AI

neutral

KOD Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitekodiak.com
Security nameKodiak Sciences Inc
Issue typecs
SectorManufacturing
Sic code2836
Employees72
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing

About Kodiak Sciences Inc

Kodiak Sciences Inc. is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, Kodiak is focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Its ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, its bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and the company is expanding its early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA.